Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021
30 nov. 2021 16h05 HE | Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies
04 nov. 2021 08h05 HE | Avid Bioservices, Inc
TUSTIN, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
TIP_link_300x300.jpg
Anatomic Pathology Market Size ($33,145.78Mn by 2028) Lead by Services Segment (40.04% Revenue Share in 2021) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
02 nov. 2021 13h23 HE | The Insight Partners
New York, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Anatomic Pathology Market: Key Insights According to our new research study on Anatomic Pathology Market Size and Forecast to 2028 - COVID-19 Impact and...
Picture1.jpg
Clearmind Medicine Files Provisional Patent Application Related to Methods of Drug-Assisted Psychotherapy
13 oct. 2021 08h00 HE | Clearmind Medicine
TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
vTv Graps Logo.png
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
23 sept. 2021 16h30 HE | vTv Therapeutics Inc.
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support...
Picture1.jpg
Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug
21 sept. 2021 07h00 HE | Clearmind Medicine
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Signs Renewable Energy Agreement With Georgia Power
21 sept. 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
researchdrivelogo.jpg
Global Antiviral Therapy Market Expected to Generate a Revenue of $79.8 Million by 2026, Growing at a CAGR of 6.7% From 2019-2026 COVID-19 Impact - Exclusive Report by Research Dive
14 sept. 2021 09h01 HE | Research Dive
New York, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global antiviral therapy market is expected to generate a revenue of $79.8 million by 2026,...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
19 août 2021 08h17 HE | InvestorBrandNetwork (IBN)
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Beroni Logo @ Dec 2019.png
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
18 août 2021 08h30 HE | Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO...